The mission of the UAB CFAR is to stimulate and support multidisciplinary basic, behavioral, clinical and translational AIDS research so as to hasten the development of effective treatments and prevention strategies for AIDS. For 20 years, the Center has played a vital role in supporting cutting edge research activities of its members that have led to paradigm-shifting discoveries, including: the discovery of HIV-1 quasispecies diversity (Nature 1988), detection of HIV-1 RNA in plasma (Science 1993), viral dynamics in acute and chronic infection (NEJM 1991;Nature 1995), HIV-1 escape from cytotoxic T-cells (Nat Medicine 1997) and neutralizing antibodies (Nature 2003), first-in-human phase 1 clinical studies of 7 currently approved therapies (NEJM 1993;Nat Medicine 1998;JAMA 2006), the zoonotic origins of HIV-1 (Nature 1999;Nature 2006;Science 2006), and the identification of the transmitted HIV-1 envelope and complete genome/proteome responsible for HIV infection (PNAS 2008). A common thread connecting all of these discoveries is the proactive participation of the CFAR in facilitating basic, translational and clinical research through effective collaboration between basic and clinical investigators. The objectives of the CFAR reflect this continuing commitment to innovative, multidisciplinary AIDS research and include: 1. To provide a central institutional focus for HIV/AIDS research activities that emphasize effective communication and collaboration among CFAR members and the wider HIV/AIDS research community. 2. To enhance productivity of ongoing research programs by encouraging interdisciplinary research and by providing critical shared resource facilities and administrative and fiscal management support to Center investigators. 3. To use robust strategic planning methods to identify new research opportunities and priorities, to align them with existing CFAR programs, and to foster new research programs where none are in existence but where faculty interest and University capacity is evident. 4. To stimulate the entry of junior and established faculty into HIV/AIDS research programs. This is accomplished through mentoring young investigators and by a peer-reviewed Developmental Grants Program. 5. To stimulate faculty recruitment and program development in areas that reflect the ongoing evolution of HIV/AIDS research and the global epidemic. The Center is comprised of 163 Center members from 35 Divisions and Departments within UAB funded by current AIDS-related grants and contracts totaling more than $87.2 million. Nine Core Facilities are proposed that provide vital support for the Center's principal thematic areas of viral pathogenesis, experimental therapeutics, global health, prevention and vaccine development. The success of the UAB CFAR in stimulating HIV/AIDS research is reflected in the growth in NIH extramural funding for AIDS-related research from $6.0 million in NIH funding in 1988 to over $26 million currently, in over 2500 research publications over the past six year grant period, in the recruitment of more than 21 HIV/AIDS investigators since 2QQ2, and in the garnering of strong Institutional support.
The UAB CFAR will stimulate and facilitate HIV/AIDS research that has high national and international impact and in so doing will promote the NIH priorities of innovation and effectiveness iin AIDS research, treatment and prevention.
|Salazar-Gonzalez, Jesus F; Salazar, Maria G; Tully, Damien C et al. (2016) Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes. Pathog Immun 1:129-153|
|Abedini-Nassab, Roozbeh; Joh, Daniel Y; Van Heest, Melissa et al. (2016) Magnetophoretic Conductors and Diodes in a 3D Magnetic Field. Adv Funct Mater 26:4026-4034|
|Dalecki, Alex G; Malalasekera, Aruni P; Schaaf, Kaitlyn et al. (2016) Combinatorial phenotypic screen uncovers unrecognized family of extended thiourea inhibitors with copper-dependent anti-staphylococcal activity. Metallomics 8:412-21|
|Pettit, April C; Mendes, Adell; Jenkins, Cathy et al. (2016) Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr 72:572-8|
|Friedman, Gregory K; Moore, Blake P; Nan, Li et al. (2016) Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro Oncol 18:227-35|
|Demark-Wahnefried, Wendy; Nix, Jeffery W; Hunter, Gary R et al. (2016) Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for BMC Cancer 16:61|
|Merlin, Jessica S; Tamhane, Ashutosh; Starrels, Joanna L et al. (2016) Factors Associated with Prescription of Opioids and Co-prescription of Sedating Medications in Individuals with HIV. AIDS Behav 20:687-98|
|Khan, Shahzada; Woodruff, Erik M; Trapecar, Martin et al. (2016) Dampened antiviral immunity to intravaginal exposure to RNA viral pathogens allows enhanced viral replication. J Exp Med 213:2913-2929|
|Kumar, Ashish; Zhang, Jennifer; Tallaksen-Greene, Sara et al. (2016) Allelic series of Huntington's disease knock-in mice reveals expression discorrelates. Hum Mol Genet 25:1619-36|
|Qin, Hongwei; Buckley, Jessica A; Li, Xinru et al. (2016) Inhibition of the JAK/STAT Pathway Protects Against Î±-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. J Neurosci 36:5144-59|
Showing the most recent 10 out of 784 publications